Section of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy.
Hypertension and Vascular Risk Unit, Department of Internal Medicine, Hospital Clínic (IDIBAPS), University of Barcelona, Barcelona, Spain.
Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):945-960. doi: 10.1093/ehjci/jex094.
Arterial hypertension (HTN) accounts for the largest amount of attributable cardiovascular (CV) mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by HTN represents an independent determinant of CV risk and the identification of target organ damage (TOD) is recommended to further reclassify patients' risk. Non-invasive CV imaging is progressively being used and continues to provide new technological opportunities to TOD evaluation at early stage. The aim of this article is to provide the community of cardiology with an update on appropriate and justified use of non-invasive imaging tests in the growing population of hypertensive patients.
动脉高血压（HTN）在全球范围内导致了最多的心血管（CV）死亡，对高血压患者进行风险分层对于管理治疗和预防不良事件至关重要。在患有 HTN 的患者中，不同器官的无症状受累是 CV 风险的独立决定因素，建议识别靶器官损伤（TOD）以进一步重新分类患者的风险。非侵入性 CV 成像技术正在被逐步采用，并不断为 TOD 的早期评估提供新的技术机会。本文旨在为心脏病学领域提供有关在不断增长的高血压患者群体中合理使用非侵入性成像检查的最新信息。
